Latest Intelligence on Cardiovascular and Diabetes in Belgium

Select information type

Refine your search

Search tips

Published within

« | 1 | » »|

Type Product title / description Pub Price

Solvay/Biovail: too little, too late for Teveten

Although Solvay/Biovail's Teveten (eprosartan) has demonstrated benefits in isolated systolic hypertension, Solvay has been reluctant to file for this indication. The results of the most recent trial may well be too little too late now that Teveten's major competitors, such as Diovan (valsartan), are also targeting this indication.

Published By Datamonitor
21 May 2003

« | 1 | » »|

No help is available.